Erratum: The severe acute respiratory syndrome coronavirus nucleocapsid inhibits type I interferon production by interfering with TRIM25-mediated RIG-I ubiquitination (Journal of Virology (2017) 91:8 (e02143-16) DOI: 10.1128/JVI.02143-16);The severe acute respiratory syndrome coronavirus nucleocapsid inhibits type I interferon production by interfering with TRIM25- mediated RIG-I ubiquitination

Journal of Virology

Volumn 91, Issue 8, 2017, Pages

  Hu, Yong ^a   Li, Wei ^a   Gao, Ting ^a   Cui, Yan ^a   Jin, Yanwen ^a   Li, Ping ^a   Ma, Qingjun ^a   Liu, Xuan ^a   Cao, Cheng ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

Interferon; Nucleocapsid; RIG I; SARS coronavirus; TRIM25

Indexed keywords

AMINO ACID; INTERFERON; NUCLEOCAPSID PROTEIN; POLYINOSINIC POLYCYTIDYLIC ACID; RETINOIC ACID INDUCIBLE PROTEIN I; TRIPARTITE MOTIF PROTEIN; TRIPARTITE MOTIF PROTEIN 25; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; NUCLEOCAPSID PROTEIN, CORONAVIRUS; PROTEIN BINDING; RNF135 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRIM25 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOMODULATION; INNATE IMMUNITY; INTERFERON PRODUCTION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PRY-SPRY DOMAIN; SARS CORONAVIRUS; SENDAI VIRUS; SIGNAL TRANSDUCTION; UBIQUITINATION; VIRUS CELL INTERACTION; VIRUS NUCLEOCAPSID; VIRUS REPLICATION; ANIMAL; CELL LINE; IMMUNE EVASION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; PATHOGENICITY; PHYSIOLOGY;

ANIMALS; CELL LINE; HUMANS; IMMUNE EVASION; IMMUNE TOLERANCE; INTERFERON TYPE I; NUCLEOCAPSID PROTEINS; PROTEIN BINDING; SARS VIRUS; TRANSCRIPTION FACTORS; TRIPARTITE MOTIF PROTEINS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION; VIRUS REPLICATION;

EID: 85016601324     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01378-20     Document Type: Erratum

References (61)

1. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh C-S, Reis e Sousa C, Matsuura Y, Fujita T, Akira S. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441:101-105. https://doi.org/10.1038/nature04734.
2. Chan YK, Gack MU. 2016. Viral evasion of intracellular DNA and RNA sensing. Nat Rev Microbiol 14:360-373. https://doi.org/10.1038/nrmicro.2016.45.
3. Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F, Reis e Sousa C. 2006. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5=-phosphates. Science 314:997-1001. https://doi.org/10.1126/science.1132998.
4. Gack MU, Albrecht RA, Urano T, Inn K-S, Huang IC, Carnero E, Farzan M, Inoue S, Jung JU, García-Sastre A. 2009. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 5:439-449. https://doi.org/10.1016/j.chom.2009.04.006.
5. Jiang F, Ramanathan A, Miller MT, Tang G-Q, Gale M, Patel SS, Marcotrigiano J. 2011. Structural basis of RNA recognition and activation by innate immune receptor RIG-I. Nature 479:423-427. https://doi.org/10.1038/nature10537.
6. Schneider WM, Chevillotte MD, Rice CM. 2014. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 32:513-545. https://doi.org/10.1146/annurev-immunol-032713-120231.
7. Akira S, Uematsu S, Takeuchi O. 2006. Pathogen recognition and innate immunity. Cell 124:783-801. https://doi.org/10.1016/j.cell.2006.02.015.
8. Bowie AG, Unterholzner L. 2008. Viral evasion and subversion of patternrecognition receptor signalling. Nat Rev Immunol 8:911-922. https://doi.org/10.1038/nri2436.
9. Katze MG, He Y, Gale M, Jr. 2002. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2:675-687. https://doi.org/10.1038/nri888.
10. Lai MM. 2003. SARS virus: the beginning of the unraveling of a new coronavirus. J Biomed Sci 10:664-675. https://doi.org/10.1007/BF02256318.
11. Becker MM, Graham RL, Donaldson EF, Rockx B, Sims AC, Sheahan T, Pickles RJ, Corti D, Johnston RE, Baric RS, Denison MR. 2008. Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice. Proc Natl Acad Sci U S A 105:19944-19949. https://doi.org/10.1073/pnas.0808116105.
12. Chen CY, Chang CK, Chang YW, Sue SC, Bai HI, Riang L, Hsiao CD, Huang TH. 2007. Structure of the SARS coronavirus nucleocapsid protein RNAbinding dimerization domain suggests a mechanism for helical packaging of viral RNA. J Mol Biol 368:1075-1086. https://doi.org/10.1016/j.jmb.2007.02.069.
13. Huang Q, Yu L, Petros AM, Gunasekera A, Liu Z, Xu N, Hajduk P, Mack J, Fesik SW, Olejniczak ET. 2004. Structure of the N-terminal RNA-binding domain of the SARS CoV nucleocapsid protein. Biochemistry 43: 6059-6063. https://doi.org/10.1021/bi036155b.
14. Surjit M, Liu B, Kumar P, Chow VT, Lal SK. 2004. The nucleocapsid protein of the SARS coronavirus is capable of self-association through a C-terminal 209 amino acid interaction domain. Biochem Biophys Res Commun 317:1030-1036. https://doi.org/10.1016/j.bbrc.2004.03.154.
15. He R, Leeson A, Ballantine M, Andonov A, Baker L, Dobie F, Li Y, Bastien N, Feldmann H, Strocher U, Theriault S, Cutts T, Cao J, Booth TF, Plummer FA, Tyler S, Li X. 2004. Characterization of protein-protein interactions between the nucleocapsid protein and membrane protein of the SARS coronavirus. Virus Res 105:121-125. https://doi.org/10.1016/j.virusres.2004.05.002.
16. Hatakeyama S, Matsuoka Y, Ueshiba H, Komatsu N, Itoh K, Shichijo S, Kanai T, Fukushi M, Ishida I, Kirikae T, Sasazuki T, Miyoshi-Akiyama T. 2008 Dissection and identification of regions required to form pseudoparticles by the interaction between the nucleocapsid (N) and membrane (M) proteins of SARS coronavirus. Virology 380:99-108. https://doi.org/10.1016/j.virol.2008.07.012.
17. Yan X, Hao Q, Mu Y, Timani KA, Ye L, Zhu Y, Wu J. 2006. Nucleocapsid protein of SARS-CoV activates the expression of cyclooxygenase-2 by binding directly to regulatory elements for nuclear factor-kappa B and CCAAT/enhancer binding protein. Int J Biochem Cell Biol 38:1417-1428. https://doi.org/10.1016/j.biocel.2006.02.003.
18. Wang Q, Li C, Zhang Q, Wang T, Li J, Guan W, Yu J, Liang M, Li D. 2010. Interactions of SARS coronavirus nucleocapsid protein with the host cell proteasome subunit p42. Virol J 7:99. https://doi.org/10.1186/1743-422X-7-99.
19. Frieman M, Heise M, Baric R. 2008. SARS coronavirus and innate immunity. Virus Res 133:101-112. https://doi.org/10.1016/j.virusres.2007.03.015.
20. Chang CK, Hsu YL, Chang YH, Chao FA, Wu MC, Huang YS, Hu CK, Huang TH. 2009. Multiple nucleic acid binding sites and intrinsic disorder of severe acute respiratory syndrome coronavirus nucleocapsid protein: implications for ribonucleocapsid protein packaging. J Virol 83: 2255-2264. https://doi.org/10.1128/JVI.02001-08.
21. Kopecky-Bromberg SA, Martinez-Sobrido L, Frieman M, Baric RA, Palese P. 2007. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol 81:548-557. https://doi.org/10.1128/JVI.01782-06.
22. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, Takeuchi O, Akira S, Chen Z, Inoue S, Jung JU. 2007. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446:916-920. https://doi.org/10.1038/nature05732.
23. Servant MJ, Grandvaux N, ten Oever BR, Duguay D, Lin R, Hiscott J. 2003. Identification of the minimal phosphoacceptor site required for in vivo activation of interferon regulatory factor 3 in response to virus and double-stranded RNA. J Biol Chem 278:9441-9447. https://doi.org/10.1074/jbc.M209851200.
24. Day CW, Baric R, Cai SX, Frieman M, Kumaki Y, Morrey JD, Smee DF, Barnard DL. 2009. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology 395:210-222. https://doi.org/10.1016/j.virol.2009.09.023.
25. Kumaki Y, Day CW, Wandersee MK, Schow BP, Madsen JS, Grant D, Roth JP, Smee DF, Blatt LM, Barnard DL. 2008. Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells. Biochem Biophys Res Commun 371:110-113. https://doi.org/10.1016/j.bbrc.2008.04.006.
26. Zielecki F, Weber M, Eickmann M, Spiegelberg L, Zaki AM, Matrosovich M, Becker S, Weber F. 2013. Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus. J Virol 87: 5300-5304. https://doi.org/10.1128/JVI.03496-12.
27. Luo H, Chen J, Chen K, Shen X, Jiang H. 2006. Carboxyl terminus of severe acute respiratory syndrome coronavirus nucleocapsid protein: self-association analysis and nucleic acid binding characterization. Biochemistry 45:11827-11835. https://doi.org/10.1021/bi0609319.
28. Durai P, Batool M, Shah M, Choi S. 2015. Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control. Exp Mol Med 47:e181. https://doi.org/10.1038/emm.2015.76.
29. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Gunther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1394-1399. https://doi.org/10.1126/science.1085952.
30. Lu G, Liu D. 2012. SARS-like virus in the Middle East: a truly bat-related coronavirus causing human diseases. Protein Cell 3:803-805. https://doi.org/10.1007/s13238-012-2811-1.
31. Hu B, Ge X, Wang LF, Shi Z. 2015. Bat origin of human coronaviruses. Virol J 12:221. https://doi.org/10.1186/s12985-015-0422-1.
32. Subissi L, Posthuma CC, Collet A, Zevenhoven-Dobbe JC, Gorbalenya AE, Decroly E, Snijder EJ, Canard B, Imbert I. 2014. One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities. Proc Natl Acad Sci U S A 111: E3900-E3909. https://doi.org/10.1073/pnas.1323705111.
33. Honda-Okubo Y, Barnard D, Ong CH, Peng BH, Tseng CT, Petrovsky N. 2015 Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol 89:2995-3007. https://doi.org/10.1128/JVI.02980-14.
34. Reghunathan R, Jayapal M, Hsu LY, Chng HH, Tai D, Leung BP, Melendez AJ. 2005. Expression profile of immune response genes in patients with severe acute respiratory syndrome. BMC Immunol 6:2. https://doi.org/10.1186/1471-2172-6-2.
35. Chan RW, Chan MC, Agnihothram S, Chan LL, Kuok DI, Fong JH, Guan Y, Poon LL, Baric RS, Nicholls JM, Peiris JS. 2013. Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J Virol 87:6604-6614. https://doi.org/10.1128/JVI.00009-13.
36. Graham RL, Donaldson EF, Baric RS. 2013. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 11:836-848. https://doi.org/10.1038/nrmicro3143.
37. Jauregui AR, Savalia D, Lowry VK, Farrell CM, Wathelet MG. 2013. Identification of residues of SARS-CoV nsp1 that differentially affect inhibition of gene expression and antiviral signaling. PLoS One 8:e62416. https://doi.org/10.1371/journal.pone.0062416.
38. Siu KL, Yeung ML, Kok KH, Yuen KS, Kew C, Lui PY, Chan CP, Tse H, Woo PC, Yuen KY, Jin DY. 2014. Middle East respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response. J Virol 88:4866-4876. https://doi.org/10.1128/JVI.03649-13.
39. Niemeyer D, Zillinger T, Muth D, Zielecki F, Horvath G, Suliman T, Barchet W, Weber F, Drosten C, Muller MA. 2013. Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist. J Virol 87:12489-12495. https://doi.org/10.1128/JVI.01845-13.
40. Yang Y, Zhang L, Geng H, Deng Y, Huang B, Guo Y, Zhao Z, Tan W. 2013. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell 4:951-961. https://doi.org/10.1007/s13238-013-3096-8.
41. Ye Y, Hauns K, Langland JO, Jacobs BL, Hogue BG. 2007. Mouse hepatitis coronavirus A59 nucleocapsid protein is a type I interferon antagonist. J Virol 81:2554-2563. https://doi.org/10.1128/JVI.01634-06.
42. Munir M. 2010. TRIM proteins: another class of viral victims. Sci Signal 3:jc2.
43. Nisole S, Stoye JP, Saib A. 2005. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 3:799-808. https://doi.org/10.1038/nrmicro1248.
44. Ozato K, Shin DM, Chang TH, Morse HC, III. 2008. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol 8:849-860. https://doi.org/10.1038/nri2413.
45. Castanier C, Zemirli N, Portier A, Garcin D, Bidere N, Vazquez A, Arnoult D. 2012. MAVS ubiquitination by the E3 ligase TRIM25 and degradation by the proteasome is involved in type I interferon production after activation of the antiviral RIG-I-like receptors. BMC Biol 10:44. https://doi.org/10.1186/1741-7007-10-44.
46. Lee NR, Kim HI, Choi MS, Yi CM, Inn KS. 2015. Regulation of MDA5-MAVS antiviral signaling axis by TRIM25 through TRAF6-mediated NF-kappaB activation. Mol Cell 38:759-764. https://doi.org/10.14348/molcells.2015.0047.
47. Manokaran G, Finol E, Wang C, Gunaratne J, Bahl J, Ong EZ, Tan HC, Sessions OM, Ward AM, Gubler DJ, Harris E, Garcia-Blanco MA, Ooi EE. 2015 Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. Science 350:217-221. https://doi.org/10.1126/science.aab3369.
48. Totura AL, Baric RS. 2012. SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr Opin Virol 2:264-275. https://doi.org/10.1016/j.coviro.2012.04.004.
49. Lu X, Pan J, Tao J, Guo D. 2011. SARS-CoV nucleocapsid protein antagonizes IFN-beta response by targeting initial step of IFN-beta induction pathway, and its C-terminal region is critical for the antagonism. Virus Genes 42:37-45. https://doi.org/10.1007/s11262-010-0544-x.
50. Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, Perlman S. 2016. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoVinfected mice. Cell Host Microbe 19:181-193. https://doi.org/10.1016/j.chom.2016.01.007.
51. Haagmans BL, Kuiken T, Martina BE, Fouchier RA, Rimmelzwaan GF, van Amerongen G, van Riel D, de Jong T, Itamura S, Chan KH, Tashiro M, Osterhaus AD. 2004. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 10:290-293. https://doi.org/10.1038/nm1001.
52. Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, Li F, Xiao C, Gao H, Yu P, Cai JP, Chu H, Zhou J, Chen H, Qin C, Yuen KY. 2015. Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 212:1904-1913. https://doi.org/10.1093/infdis/jiv392.
53. Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, Pham DH, Deif H, LaMere EA, Chang M, Kain KC, Farcas GA, Ferguson P, Latchford M, Levy G, Dennis JW, Lai EK, Fish EN. 2003. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 290:3222-3228. https://doi.org/10.1001/jama.290.24.3222.
54. Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, Yin Z, Huang S, Deng Z, Wei M, Xiong J, Hawkey PM. 2003. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 52:715-720. https://doi.org/10.1099/jmm.0.05320-0.
55. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. 2014. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 20:42-46. https://doi.org/10.1016/j.ijid.2013.12.003.
56. Bitzer M, Lauer U, Baumann C, Spiegel M, Gregor M, Neubert WJ. 1997. Sendai virus efficiently infects cells via the asialoglycoprotein receptor and requires the presence of cleaved F0 precursor proteins for this alternative route of cell entry. J Virol 71:5481-5486.
57. Park MS, Shaw ML, Munoz-Jordan J, Cros JF, Nakaya T, Bouvier N, Palese P, Garcia-Sastre A, Basler CF. 2003. Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol 77:1501-1511. https://doi.org/10.1128/JVI.77.2.1501-1511.2003.
58. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25:402-408. https://doi.org/10.1006/meth.2001.1262.
59. Cao C, Leng Y, Kufe D. 2003. Catalase activity is regulated by c-Abl and Arg in the oxidative stress response. J Biol Chem 278:29667-29675. https://doi.org/10.1074/jbc.M301292200.
60. Mossel EC, Wang J, Jeffers S, Edeen KE, Wang S, Cosgrove GP, Funk CJ, Manzer R, Miura TA, Pearson LD, Holmes KV, Mason RJ. 2008. SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells. Virology 372:127-135. https://doi.org/10.1016/j.virol.2007.09.045.
61. Gillim-Ross L, Taylor J, Scholl DR, Ridenour J, Masters PS, Wentworth DE. 2004 Discovery of novel human and animal cells infected by the severe acute respiratory syndrome coronavirus by replication-specific multiplex reverse transcription-PCR. J Clin Microbiol 42:3196-3206. https://doi.org/10.1128/JCM.42.7.3196-3206.2004.